The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments

Recruiting

• Conditions: Neoadjuvant Chemotherapy; Neoadjuvant Chemoradiotherapy; Systemic Inflammatory Response Syndrome (SIRS); Nutrition Aspect of Cancer; Gastric Cancer

• Registration Number: NCT03493880
• Lead Sponsor: Peking University

Brief Summary

Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer. With the increasing application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues concerning how are the immuno-nutrition index be altered under the effects of perioperative treatments and what are the clinical values of these index should be clarified.

Detailed Description

The immune (systemic inflammation) index includes:

NLR (Neutrophil-to-Lymphocyte Ratio); PLR (Platelet-to-Lymphocyte Ratio); SII (Systemic Immune-Inflammation Index); GPS (Glasgow Prognostic Score); mGPS (modified Glasgow Prognostic Score); PI (Prognostic Index);

The nutrition index includes:

NRS2002; PNI (Prognostic Nutrition Index);

Study Timeline

• Study Start: 2015-09-01
• Study First Submitted: 2018-03-22
• Status Verified: 2018-04
• Study First Submitted QC: 2018-04-10
• Last Update Submitted: 2018-04-10
• Study First Posted: 2018-04-11
• Last Update Posted: 2018-04-11
• Primary Completion: 2020-09-01
• Study Completion: 2025-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Histologically confirmed adenocarcinoma
• Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy
• Diagnosed clinical advanced gastric cancer or esophagogastric cancer

Exclusion Criteria

• Lack of immuno-nutrition data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pathological response	One month after surgery	Pathological response

Secondary Outcome Measures

Name	Time	Method
3-years disease-free survival	Three years after surgery	3-years disease-free survival
yp TNM Stage	One month after surgery	yp TNM Stage
Postoperative morbidity	One month after surgery	Postoperative morbidity
3-years overall survival	Three years after surgery	3-years overall survival

Trial Locations

Locations (1)

Peking University Cancer Hospital; 🇨🇳 Beijing, Beijing, China